|Articles|February 1, 2000

Creating an Optimal Strategy for Improving Outcomes in Depression
Volume 6
Issue 2 Suppl

Selected Abstracts

Download PDF: Selected Abstracts

Articles in this issue

over 26 years ago

Article

The Role of Primary Care in the Treatment of Depression

over 26 years ago

Article

Continuing Pharmacy/Medical Education Quiz

over 26 years ago

Article

Bibliography

over 26 years ago

Article

Participating Faculty

over 26 years ago

Article

Introduction

over 26 years ago

Article

Critical Issues in the Management of Depression

over 26 years ago

Article

Patient Compliance in Depression

over 26 years ago

Article

Pharmacokinetics and Pharmacodynamics of Antidepressant Medications

over 26 years ago

Article

Managed Care Cost-Containment Strategies and Their Impact on Physician Prescribing and Treatment of Depression

over 26 years ago

Article

Improving Depression Treatment in Managed Primary Care Practices

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Selected Abstracts

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Selected Abstracts

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention